Study of Efficacy and Safety of LEE011 in Men and Postmenopausal Women With Advanced Breast Cancer.

Completed · Phase 3 · Has a placebo group

Conditions studied: Advanced Breast Cancer

In brief

The main aim of this study was to evaluate the efficacy and safety of adding ribociclib to fulvestrant in men and postmenopausal women with hormone receptor positive (HR+), HER2-negative advanced breast cancer.

Key facts

Study ID
NCT02422615
Run by
Novartis Pharmaceuticals
People needed
726
Starts
2015-06-09
Expected to finish
2023-01-11
Last updated by the study team
2023-11-30

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.